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Abstract
West Nile virus (WNV) continues to circulate in the USA and forms a threat to the rest of the Western hemisphere. Since
methods for the treatment of WNV infections are not available, there is a need for the development of safe and effective
vaccines. Here, we describe the construction of a recombinant influenza virus expressing domain III of the WNV
glycoprotein E (Flu-NA-DIII) and its evaluation as a WNV vaccine candidate in a mouse model. FLU-NA-DIII-vaccinated mice
were protected from severe body weight loss and mortality caused by WNV infection, whereas control mice succumbed to
the infection. In addition, it was shown that one subcutaneous immunization with 105 TCID50 Flu-NA-DIII provided 100%
protection against challenge. Adoptive transfer experiments demonstrated that protection was mediated by antibodies and
CD4+T cells. Furthermore, mice vaccinated with FLU-NA-DIII developed protective influenza virus-specific antibody titers. It
was concluded that this vector system might be an attractive platform for the development of bivalent WNV-influenza
vaccines.
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Introduction
West Nile Virus (WNV) belongs to the genus Flavivirus and is
maintained in an enzootic cycle involving birds and mosquitoes,
with humans and horses as ‘‘dead-end’’ hosts. WNV is circulating
in the USA since 1999 and has infected more than 25,000 people
with mortality rates of up to 2% [1]. Especially the elderly are at
risk for developing severe disease and a poor outcome of infection,
which may be attributed to an age-related decline of immune
function [2,3,4]. Evidence is accumulating that the virus is moving
southwards, putting millions of people in South-America and the
Caribbean at risk [5,6]. Several outbreaks of WNV infections in
Europe indicate that the virus may also emerge in West European
countries [7,8,9,10]. Effective drugs for the treatment of WNV
infections are not available and therefore safe and effective
vaccines are needed to protect populations at risk. Several vaccine
candidates have been tested in animal models
[11,12,13,14,15,16,17,18,19,20]. Most of these vaccine candidates
are based on the glycoprotein E (gE), which is a target for the
induction of virus-neutralizing antibody responses. In addition, the
gE may be a target for T-cell responses [21]. The gE of flaviviruses
consists of three domains (DI- DIII). DI and DII contain most of
the cross-reactive B-cell epitopes and DIII most of the type-specific
and neutralizing B-cell epitopes [16,22,23,24]. Subunit vaccines
based on DIII have been evaluated and proven effective in
preventing severe infection in mouse models [11,12]. However,
high doses of recombinant DIII protein were needed to induce
neutralizing antibody responses, indicating that DIII was poorly
immunogenic. Elderly people that are at risk for severe WNV
disease are also at risk for complications associated with influenza
virus infections. Influenza viruses are an important cause of
respiratory tract infections, affecting 5–10% of the human
population annually with case-fatality rates of up to 1% [25,26].
For the prevention of influenza and its complications, annual
vaccination of high risk groups including patients with chronic
disease, immune-compromised subjects and the elderly is recom-
mended. Therefore, the availability of vaccines that could protect
both against WNV and influenza virus infection would be
desirable.
Here we describe the construction of a recombinant influenza
virus vector that expresses DIII of the WNV gE protein. We
hypothesized that the multimeric expression of DIII on recombi-
nant influenza virus-infected cells or its presence on vector
particles would increase its immunogenicity resulting in the
induction of high titers of WNV neutralizing antibodies. Using
influenza virus as a vector not only protective immunity was
induced against WNV, but also against the vector. It was
concluded that the use of recombinant influenza virus expressing
WNV DIII is a promising approach that could afford protection
against both viruses.
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Materials and Methods
Cells
Madin-Darby canine kidney (MDCK; ATCC, CRL 1708) and
Vero E6 cells were cultured in Eagle’s minimal essential medium
supplemented with non-essential amino acids, 100 IU/ml penicil-
lin, 100 mg/ml streptomycin, 2 mM L-glutamine, 2% sodium
bicarbonate, 1% HEPES, and 10% Fetal Bovine Serum (FBS) (all
from BioWhittaker, Verviers, Belgium).
Construction of DIII-expressing recombinant influenza
virus
A recombinant attenuated influenza virus was constructed that
expresses WNV DIII as a structural envelope protein. To this end,
the region encoding DIII was amplified by RT-PCR using RNA
extracted from WNV-NY99 infected Vero E6 cells. Subsequently,
the 370 bp fragment was amplified using primers with respectively
EcoRI and SpeI restriction sites (Fw: tggaattcATGGAACAACC-
TATGGCGTCT; Rev: gactagTCAATGATGATGATGAT-
GATGGTCGA) and directionally cloned in frame with the N-
terminal region of the influenza virus neuraminidase (NA), a type II
membrane glycoprotein, essentially as described for recombinant
influenza virus expressing green fluorescent protein (GFP) [27]. For
generation of recombinant influenza viruses, bi-directional plasmids
based on the gene segments of influenza virus strain A/PR/8/34
were used [28,29]. The chimeric NA reverse-genetics plasmid was
co-transfected with plasmids encoding PB1, PB2, PA, NP, HA, NS,
and M1/M2 of influenza virus A/PR/8/34 [27,28,29,30] into
293T cells and subsequently virus was rescued after passage in
MDCK cells. Since this virus lacks a functional NA, virus was
propagated in the presence of exogenous NA derived from V.
cholera (Sigma). The virus was designated FLU-NA-DIII and a
recombinant influenza virus expressing green fluorescent protein
(FLU-NA-GFP) was used as negative control virus [27] in the
experiments described below. To characterize FLU-NA-DIII, RT-
PCR was performed with DIII- and influenza virus M1-specific
primer sets (available on request). The identity of FLU-NA-DIII was
further confirmed by sequence analyses of the PCR products.
Characterization of recombinant virus
To confirm expression of recombinant protein, MDCK cells were
infected with Flu-NA-DIII at an MOI of 0.01, without addition of
exogenous NA. Cells were fixed with ice-cold methanol 20 hours
later and incubated with mouse anti-influenza NP monoclonal
antibody (ATCC, clone HB65), mouse anti-WNV polyclonal serum
or a mouse anti-DIII monoclonal antibody (7H2; Bioreliance Corp.,
Rockville, USA). Horseradish peroxidase-labelled rabbit anti-mouse
immunoglobulin (Dako, Glostrup, Denmark) was used as conjugate.
The presence of specific antigens was demonstrated using 3-amino-
9-ethylcarbazole (AEC, Sigma) as substrate according to the
manufacturer’s instructions. Alternatively, cells were harvested and
lysed in buffer containing 150 mM NaCl, 1 g/L Nonidet-P40,
0,5 g/L sodiumdexycholate, 0,1 g/L SDS, 50 mM Tris.HCl.
Proteins were separated by electrophoresis in 12% polyacryamide
gel and subsequently transferred onto polyvinyldichloride difluoride
Hybond-P membrane (Amersham Bioscience, UK). Membranes
were incubated with either mouse anti-influenza NP monoclonal
antibody or mouse anti-WNV polyclonal serum, and developed
using a chemo-luminescence substrate according to manufacturer’s
instructions (ECL, Amersham).
Vaccination-challenge experiments
In the first set of experiments, groups of six-weeks old C57BL/6
mice (n = 8 per group) were immunized twice either by the intra-nasal
(i.n.) or the subcutaneous (s.c.) route using a dose of 106 TCID50 of
sucrose-gradient purified influenza viruses (FLU-NA-DIII or FLU-
NA-GFP). Animals were immunized on day 0 and 14 and blood
samples were collected on days 0, 14 and 42. Serum samples were
tested for the presence of DIII-specific antibodies by ELISA and virus
neutralization assay as described previously [12]. Neutralizing titers
were expressed as the reciprocal of the highest serum dilution still
giving 100% suppression of cytopathic effect. ELISA titers were
expressed as the reciprocal of the highest serum dilution that resulted
in an optical density higher than 0.200. Titers ,50 were considered
negative based on cutoff values established with sera from mice not
infected with WNV. In addition, sera were tested for the presence of
influenza virus specific antibodies. To this end, sera were treated with
cholera filtrate and after heat inactivation serial two-fold dilutions
were prepared. A hemagglutination inhibition (HI) assay was
performed using a standard protocol with 1% turkey erythrocytes
and 4 HA unit of influenza virus A/PR/8/34 as described [31]. All
animal experiments were approved by the animal ethics committee of
the Erasmus MC Rotterdam, The Netherlands.
IFN-c ELISPOT was used as indicator for the induction of
DIII-specific T-cell responses in the spleen. Plates were coated
overnight with 1,5 mg/well of anti-IFN-c antibody (AN18;
Mabtech, Germany). Splenocytes were cultured in triplicates at
a density of 26105 cells per well in a volume of 150 ml at 37uC and
stimulated 10 mM DIII derived peptide 39f (VNPFVSVATA-
NAKVL). After incubation for 48 hours at 37uC in 5% CO2,
plates were washed thoroughly and incubated with 1 mg/ml
biotin-conjugated anti-IFN-c antibody (R4-6A2; Mabtech). Plates
were developed by adding GABA-labeled-streptavidin (U-cyTech,
Utrecht, Netherlands) according to the manufacturer’s instruc-
tions, and spots were counted using an ELISPOT reader
(Bioreader 3000, Bio-Sys GmbH).
To determine the dose-protection range, groups of mice (n = 8)
were immunized twice (day 0 and 14) s.c with 101, 102, 103, 104,
and 105 TCID50 of sucrose-gradient purified FLU-NA-DIII or
FLU-NA-GFP.
On day 42 post vaccination, all animals were infected
subcutaneously with a lethal dose of WNV-NY99 (16106
TCID50). Mice in all groups were observed each day for illness,
weight loss, and death for a period of 14 days.
Passive transfer experiments
To assess which arm of the adaptive immune response was
responsible for protection against challenge infection, adoptive
transfer experiments were performed using serum, purified CD4+T
cells and CD8+T cells obtained 4 weeks after the booster
immunization with FLU-NA-DIII or FLU-NA-GFP. MACS mag-
netic beads (Miltenyi Biotec, Auburn, CA) were used to separate the
CD4+ (L3T4) and CD8a+ (Ly-2) T-cell fractions from mouse
splenocytes, as instructed by the manufacturer, which yielded purified
CD3+CD4+ and CD3+CD8+T cell preparations with ,0.5%
contaminating cells. Lymphocytes were washed three times with,
and resuspended in phosphate-buffered saline (PBS). Eight weeks old
recipient mice (n = 5) received 200 ml immune serum, 56105 CD4+
or 56105 CD8+T cells by the intra-peritoneal route. Four hours post
transfer the animals were infected by the s.c. route with 100 TCID50
of WNV-NY99, which is a lethal dose for mice of this age. Eight days
after challenge, all mice were sacrificed and the virus titers in the
brains were determined as described previously [12].
Statistical analysis
Differences in Kaplan-Meier survival curves between the groups
were assessed using the log-rank test. Data for serum antibody titers
and viral titers in brains were analysed using the two-sided Student’s
Influenza Virus Vaccine Vector
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t test. All statistical analyses were performed using GraphPad Prism
version 4 software (Graphpad Software, San Diego, USA). Values of
P#0.05 were considered statistically significant.
Results
Vaccine Characterization
As shown in figure 1A, with the influenza virus M1 primer set a
signal of 1.1 kb was observed with the RNA extracted from both
FLU-NA-DIII and FLU-NA-GFP virus stocks, while only the DIII
primer set resulted in an amplicon of 451 bp with FLU-NA-DIII. Also
nucleotide sequence analysis confirmed the identity of both viruses.
As expected, the recombinant influenza virus Flu-NA-DIII was
unable to spread in culture due to lack of NA activity. The fact that
no infectious virus could be recovered from MDCK cells infected
with Flu-NA-DIII in presence of trypsin up to three days after
infection, indicated that no wildtype influenza virus was present in
the recombinant viral stock. Increase in Flu-NA-DIII titers was only
observed in vitro after addition of exogenous NA in a dose-dependent
way. The minimal concentration of exogenous NA needed for
optimal propagation of NA deficient Flu-NA-DIII was 0.1 mIU/
ml. Next, Western blot analysis performed with cell lysates of virus-
infected MDCK cells and antibodies directed against influenza virus
NP and WNV DIII, showed that both FLU-NA-DIII and FLU-NA-
GFP expressed influenza virus NP, which was also detected in
purified virus preparations (figure 1B). In contrast, the presence of
the 15 kDa DIII was only observed in FLU-NA-DIII infected cell
lysates and purified FLU-NA-DIII preparations. The presence of
Figure 1. Characterization of recombinant influenza A viruses. RT-PCR analysis of Flu-NA-GFP and Flu-NA-DIII RNA extracted from MDCK cells
20 hours after infection (A). Amplicons were separated in 1% agarose gel. For amplification WNV-DIII (lanes 2 and 3) and influenza A (lanes 6 and 7)
virus-specific primers were used. Expression of DIII was analyzed by Western blot analysis (B). Viral proteins in lysates of infected cells or in sucrose
gradient purified virus preparations were separated by SDS-PAGE and transferred to PDVF membranes, which were incubated with a DIII specific
monoclonal antibody 7H2 (upper panel) or an influenza virus NP specific monoclonal antibody (ATCC, clone HB65; lower panel). Expression of DIII was
also confirmed by immuno-staining of MDCK cell infected with FLU-NA-GFP and FLU-NA-DIII (moi = 0.01) with NP- and DIII-specific antibodies as
indicated (C).
doi:10.1371/journal.pone.0018995.g001
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GFP in influenza virus FLU-NA-GFP infected cells and purified
virus preparations was demonstrated previously [27]. The expres-
sion of DIII was also demonstrated in infected cells with an
immunostaining technique using WNV-specific antibodies
(Figure 1C). Thus, an attenuated NA-deficient recombinant
influenza virus was constructed that expresses WNV-DIII and
carries the DIII as a structural envelope protein.
Immunogenicity and efficacy studies
As shown in figure 2, both i.n and s.c immunization with FLU-
NA-DIII induced DIII-specific antibodies. The s.c route was more
efficient than the i.n route both in terms of induction of virus-
neutralizing titers (Figure 2A) and WNV-specific IgG ELISA titers
(Figure 2B). On day 14 slightly higher neutralizing antibody titers
(range: 20–80) were measured in mice vaccinated s.c with Flu-NA-
DIII, compared to the mice that received the same vaccine i.n
(range: 10–40). A clear booster response was seen in all animals
that received the Flu-NA-DIII four weeks after second vaccination,
resulting in statistically significant differences between groups that
were vaccinated i.n and s.c (P,0.001). The use of FLU-NA-GFP
did not induce DIII-specific antibodies. In addition, immunization
with FLU-NA-DIII induced WNV DIII specific cellular immune
responses as detected in an IFN-c ELISPOT assay after
stimulation of splenocytes with a DIII derived peptide
Figure 2. Induction of WNV-specific immune responses by vaccination with FLU-NA-DIII. WNV-neutralizing antibodies were detected by
virus neutralization assay (A) and DIII-specific IgG antibodies by ELISA (B) in serum obtained from mice vaccinated with FLU-NA-DIII i.n. (N) or s.c. (m)
and FLU-NA-GFP i.n. (#) or s.c. (n) at the indicated time points. Arrows indicate time points of vaccination. The data are expressed as average titers
per group (n = 10) 6 SD. Cellular DIII-specific responses were determined by IFN- c ELISPOT assay (C). Splenocytes obtained on day 42 were
stimulated with 10 mM peptide (VNPFVSVATANAKVL) and the numbers of cells producing IFN-c per 26105 cells were determined in mice vaccinated
with FLU-NA-DIII or FLU-NA-GFP as indicated. Each experiment was performed twice in triplicate. Results are indicated as mean6 standard deviation.
Induction of Hemagglutination titers after immunization with FLU-NA-DIII and FLU-NA-GFP. Mice (n = 8) were immunized intranasally (i.n.) or
subcutaneously (s.c.) with Flu-NA-DIII or FLU-NA-GFP (D).
doi:10.1371/journal.pone.0018995.g002
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(VNPFVSVATANAKVL) representing a T helper cell epitope
(Figure 2C). Consistent with the antibody responses, the IFN-c
response was significantly higher in mice vaccinated s.c as
compared to i.n. vaccinated animals (P,0.05). Four weeks after
second vaccination, all mice developed antibody responses against
the homologous influenza virus A/PR/8/34 in the HI assay. After
two immunizations with either FLU-NA-DIII or FLU-NA-GFP,
mice that received the vaccine by the i.n and the s.c routes
developed detectable antibody titers (Figure 2D). Four weeks after
the second immunization these animals had HI titers ranging from
40–160, with higher titers measured in the groups that received
the vaccine subcutaneously.
To assess the protective efficacy of the immune responses
induced with FLU-NA-DIII and FLU-NA-GFP, groups of ten
mice were challenged with a lethal dose of 106 TCID of WNV-
NY99 given subcutaneously. Mice vaccinated with FLU-NA-GFP
developed clinical signs characterized by ruffled fur and hunched
posture six days after infection onward, lost around 20% of their
body weight eight days post infection, and all animals died or had
to be taken out of the experiment within eight days post infection
(Figure 3). Weight losses were first observed around day 6 post
infection, which coincided with signs of paralysis. In contrast, mice
vaccinated with FLU-NA-DIII lost body weight at a slower rate
and eventually recovered from the infection with WNV-NY99.
Especially subcutaneously vaccinated mice suffered less from the
infection, lost weight minimally, and recovered quickly. Survival
rates were 100% and 75% after s.c and i.n vaccination with FLU-
NA-DIII, respectively. FLU-NA-GFP vaccinated mice were not
protected from infection, which indicates that innate immune
responses were not responsible for the observed protection.
Adoptive transfer experiments were performed to study
correlates of protection. Mice that received serum, CD4+ or
CD8+T cells obtained from FLU-NA-GFP vaccinated mice lost
up to 20% of their body weight and had mean brain virus titers of
103.8 TCID50/gram tissue. In contrast, transfer of FLU-NA-DIII
immune serum to naı¨ve recipient mice reduced the weight loss and
virus replication in the brain significantly (P,0.05; figure 4 A and
B). A similar effect was observed after the transfer of CD4+T-cells
obtained from FLU-NA-DIII vaccinated mice (P,0.05; Figure 4C
and D), whereas the transfer of FLU-NA-DIII immune CD8+T
cells did not confer any protection against disease caused by
infection with WNV-NY99 (Figure 4E and F).
To determine the dose-range of FLU-NA-DIII able to induce
protective immunity after two immunizations, groups of mice were
immunized with a range of doses (101–106). Doses ranging from
101–103 did not protect animals against lethal infection (Table 1).
Immunization with 104 TCID50 of FLU-NA-DIII resulted in 75%
(6/8) survival, while 105 and 106 TCID50 FLU-NA-DIII protected
100% mice against lethal infection. To investigate whether one
immunization could offer protection, mice were immunized once
with either 105 or 106 TCID50 FLU-NA-DIII. On day 42 mice
were challenged WNV. Both doses resulted in 100% survival after
one immunization, whereas animals that received FLU-NA-GFP
were not protected.
Discussion
In the light of the continuing threat of WNV to the western
hemisphere, the availability of a safe and effective vaccine is
crucial. In the present study we have evaluated the immunoge-
nicity and protective efficacy of a recombinant influenza virus
expressing DIII of WNV in a mouse model. These data confirm
that vaccine-induced humoral and CD4+T cell responses
contribute to protective immunity against WNV challenge
infection. The protective role of antibodies against WNV has
been demonstrated in various studies [32,33,34]. Several epitopes
have been defined on gE of WNV, involved in cell attachment,
trimerization and fusion. The epitopes that induce potent
neutralizing antibodies are located on the upper lateral surface
of DIII, and these antibodies can block infection efficiently at a
post-entry step [35,36,37].
In addition to DIII-specific antibodies, our results show that
DIII-specific CD4+T-cells provided partial protection against
neuro-invasive disease in mice, which is in concordance with
previous studies showing the protective effects of gE-specific
Figure 3. Loss of body weight after challenge-infection with
WNV. Mice (n = 8) were vaccinated intranasally with Flu-NA-DIII (N) or
Flu-NA-GFP (#) or by the subcutaneous route (m and n, respectively).
The daily weights of each animal were calculated compared to their
respective weight on the day of challenge, and data are shown as the
average percentage of initial weight for each group. Error bars
represent the standard error for all samples available at that time
point. Subsequently, the mice were challenged subcutaneously with
106 TCID50 WNV-NY99 and weighed daily. The mean body weight is
expressed as the percentage of the body weight before challenge
infection (A). The survival rates of mice after challenge infection with
WNV-NY99 are depicted as Kaplan-Meier survival curves (B). The
difference in survival rate between Flu-NA-DIII and Flu-NA-GFP
vaccinated mice was statistically significant as determined by the
logrank test. The symbols for the respective groups are the same as in
panel A.
doi:10.1371/journal.pone.0018995.g003
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CD4+T cells [38,39]. Here we show that CD4+T cell responses
specific for the ectodomain of DIII, were sufficient to afford partial
protection against WNV virus infection. The mechanism underly-
ing the protective effect of these CD4+T-cells is unclear, but levels of
IFN-c production inversely correlated with virus titers in the brain.
Several studies have shown that CD8+T cells play a role in
elimination of WNV from infected tissues and protection against
lethal disease [40,41,42,43]. Adoptively transferred CD8+T cells
obtained from FLU-NA-DIII vaccinated mice failed to confer
protection in the present study, which may be attributed to the
absence of CTL epitopes in DIII recognized by C57BL/6 mice.
Attenuated recombinant influenza viruses have been proposed
as attractive vaccine vectors, since they are highly immunogenic in
the absence of virulence [44,45,46,47,48]. Also NA-deficient
influenza viruses have been suggested as safe and potent vector
vaccine candidates [48,49]. An additional advantage of using NA
deficient influenza A virus is that it can be used as a safe and
effective vaccine against seasonal influenza. Both the FLU-NA-
GFP and FLU-NA-DIII recombinant viruses induced antibody
responses against influenza virus A/PR/8/34. Serum HI titers of
$40 are considered to be protective against influenza [50], and
vaccination with the NA deficient virus met these minimal
Figure 4. Protection against challenge infection is mediated by humoral and CD4+T cell responses. Recipient mice received serum (A
and B) CD4+T cells (C and D) or CD8+T cells (E and F) obtained from mice that were vaccinated with FLU-NA-DIII (closed symbols) or FLU-NA-GFP
(open symbols) by the i.n route (N and# respectively) or s.c. (m and n respectively) and were subsequently infected with 100 TCID50 WNV-NY99.
Loss of body weight (A,C and E) and virus titers in the brain were determined eight days post challenge infection (B, D and F). The results represent
the mean values of groups of five mice. Error bars indicate the standard deviation; * indicates a statistically significant difference compared to control
groups receiving serum or T cells from FLU-NA-GFP vaccinated mice (determined by t test). The daily weights of each animal were calculated
compared to their respective weight on the day of challenge, and data are shown as the average percentage of initial weight for each group (A, C, E).
Error bars represent the standard error for all samples available at that time point.
doi:10.1371/journal.pone.0018995.g004
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requirements. Therefore it is anticipated that the use of these
attenuated influenza viruses will afford protection against infection
with homologous viruses.
Several vectored vaccines have been developed against WNV
[19,51,52,53,54,55], most of them tested as candidate vaccines for
human use. In most of these studies the vectored vaccines
expressed the secreted form of WNV glycoprotein E, which were
administered twice either via the intraperitoneal or the subcuta-
neous route and resulted in 80–100% efficacy. One study describes
the administration of a recombinant vesicular stomatitis virus
vaccine via the intranasal route, which resulted in 80% survival
rates [54], in line with the data presented in this manuscript. Our
study is the first to describe the use of domain III of WNV
glycoprotein E, with efficacy rates similar to vectored vaccines
expressing the complete glycoprotein E of WNV.
In this study, the use of recombinant influenza virus as vector
for the delivery of WNV DIII resulted in WNV-specific immune
responses and HI titers greater than 40. Subcutaneous immuni-
zation was more efficient than intranasal administration of the
vaccine, which was included as well since influenza viruses
typically target the respiratory tract. Apparently, the route of
administration affected the outcome of the immune responses and
the protective potential of this candidate vaccine, which was
demonstrated also for other vaccine preparations [56,57,58]. The
influenza virus specific antibody levels that were induced in all
vaccinated mice indicated that these animals were protected
against infection with influenza A/PR/8/34 as well.
Collectively, the data presented in the present study indicate
that an attenuated NA-deficient recombinant influenza virus is a
promising bivalent vector-vaccine candidate for the induction of
DIII-and HA-specific antibodies as well as DIII-specific T cells.
Especially subcutaneous administration of FLU-NA-DIII induced
strong immune responses and afforded substantial protection
against infection with WNV-NY99 in mice. Further studies are
ongoing to determine how soon after immunization the vaccine is
effective and the level and longevity of protection provided by a
single immunization. Further evaluation of this vector system as a
WNV and influenza A virus bi-valent vaccine seems warranted.
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